Literature DB >> 26519784

Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort.

Amy L Turitz1, Jamie A Bastek2, Stephanie E Purisch2, Michal A Elovitz2, Lisa D Levine2.   

Abstract

BACKGROUND: Preterm birth (PTB) remains a significant cause of neonatal morbidity and mortality. Women with a prior PTB are at risk for recurrent PTB. Treatment with 17-alpha hydroxyprogesterone caproate (17OHP-C) has become standard of care for women with prior PTB to help reduce this risk. Factors that affect a woman's decision to use this medication are largely unknown.
OBJECTIVE: The objective of our study was to investigate patient-level barriers to 17OHP-C. We studied a cohort of women eligible for 17OHP-C with the hypothesis that 17OHP-C is underutilized and certain patient characteristics, such as obstetrical history, influence its use. STUDY
DESIGN: A cross-sectional study of all women seen at a specialty prematurity clinic from 2009 through 2013 was performed. Women with a singleton pregnancy were included if they had a prior spontaneous PTB (sPTB). The χ(2) tests were performed for univariate analyses. Multivariable logistic regression was used to control for confounders.
RESULTS: In all, 243 women had 17OHP-C recommended to them based on obstetrical history. There were 218 women with a pregnancy during our study period that were included in our analysis. A total of 163 (74.7%) had documented 17OHP-C use. Women were more likely to accept 17OHP-C if they had a history of a second-trimester loss only (odds ratio [OR], 2.32; 95% confidence interval [CI], 1.17-4.58) or received recommendation for cerclage due to a short cervical length (OR, 4.12; 95% CI, 1.55-10.99). Women with a prior full-term birth were less likely to accept 17OHP-C (OR, 0.48; 95% CI, 0.26-0.89), especially when the prior full-term birth was subsequent rather than prior to the PTB (OR, 0.19; 95% CI, 0.08-0.47). Race, obesity, and insurance status did not impact 17OHP-C use. There was no difference in the rate of sPTB between those who used and did not use 17OHP-C (37.2 vs 34.0%, P = .7).
CONCLUSION: Obstetric history impacted 17OHP-C use. This study identifies biases regarding 17OHP-C at the patient level and can be used to develop strategies to increase its use. However, the similarity in the sPTB rate between users and nonusers highlights the importance of identifying specific populations where 17OHP-C is and is not effective in preventing PTB.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  17-alpha hydroxyprogesterone caproate; acceptance; barriers; prematurity prevention program; preterm birth

Mesh:

Substances:

Year:  2015        PMID: 26519784      PMCID: PMC4808591          DOI: 10.1016/j.ajog.2015.10.148

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  16 in total

1.  Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey.

Authors:  Amen Ness; Todd Dias; Karla Damus; Irina Burd; Vincenzo Berghella
Journal:  Am J Obstet Gynecol       Date:  2006-10       Impact factor: 8.661

2.  ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth.

Authors: 
Journal:  Obstet Gynecol       Date:  2008-10       Impact factor: 7.661

3.  Patients with an ultrasonographic cervical length < or =15 mm have nearly a 50% risk of early spontaneous preterm delivery.

Authors:  S S Hassan; R Romero; S M Berry; K Dang; S C Blackwell; M C Treadwell; H M Wolfe
Journal:  Am J Obstet Gynecol       Date:  2000-06       Impact factor: 8.661

Review 4.  17 hydroxyprogesterone for the prevention of preterm delivery.

Authors:  Paul J Meis
Journal:  Obstet Gynecol       Date:  2005-05       Impact factor: 7.661

5.  Mid-trimester endovaginal sonography in women at high risk for spontaneous preterm birth.

Authors:  J Owen; N Yost; V Berghella; E Thom; M Swain; G A Dildy; M Miodovnik; O Langer; B Sibai; D McNellis
Journal:  JAMA       Date:  2001-09-19       Impact factor: 56.272

6.  Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.

Authors:  Joann R Petrini; William M Callaghan; Mark Klebanoff; Nancy S Green; Eve M Lackritz; Jennifer L Howse; Richard H Schwarz; Karla Damus
Journal:  Obstet Gynecol       Date:  2005-02       Impact factor: 7.661

7.  Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length.

Authors:  John Owen; Gary Hankins; Jay D Iams; Vincenzo Berghella; Jeanne S Sheffield; Annette Perez-Delboy; Robert S Egerman; Deborah A Wing; Mark Tomlinson; Richard Silver; Susan M Ramin; Edwin R Guzman; Michael Gordon; Helen Y How; Eric J Knudtson; Jeff M Szychowski; Suzanne Cliver; John C Hauth
Journal:  Am J Obstet Gynecol       Date:  2009-10       Impact factor: 8.661

8.  ACOG Committee Opinion. Use of progesterone to reduce preterm birth.

Authors: 
Journal:  Obstet Gynecol       Date:  2003-11       Impact factor: 7.661

Review 9.  Prediction and prevention of recurrent spontaneous preterm birth.

Authors:  Catherine Y Spong
Journal:  Obstet Gynecol       Date:  2007-08       Impact factor: 7.661

10.  Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.

Authors:  Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

View more
  5 in total

1.  Appropriate Use of Progesterone to Prevent Preterm Birth: Approaches to Measurement for Driving Improvement.

Authors:  Priya Batra; Ashley Hirai; Sabrina Selk; Vanessa Lee; Michael Lu
Journal:  Matern Child Health J       Date:  2017-03

2.  Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis.

Authors:  Rupsa C Boelig; Luigi Della Corte; Sherif Ashoush; David McKenna; Gabriele Saccone; Shalini Rajaram; Vincenzo Berghella
Journal:  Am J Obstet Gynecol MFM       Date:  2019-03-27

3.  Pregnant women's preferences for and concerns about preterm birth prevention: a cross-sectional survey.

Authors:  Vanessa Ha; Sarah D McDonald
Journal:  BMC Pregnancy Childbirth       Date:  2017-01-31       Impact factor: 3.007

4.  Understanding if, How, and Why Women with Prior Spontaneous Preterm Births are Treated with Progestogens: A National Survey of Obstetrician Practice Patterns.

Authors:  Jack R Gallagher; Jennifer Gudeman; Kylee Heap; Joy Vink; Susan Carroll
Journal:  AJP Rep       Date:  2018-11-01

Review 5.  Risk of recurrent spontaneous preterm birth: a systematic review and meta-analysis.

Authors:  Courtney Phillips; Zain Velji; Ciara Hanly; Amy Metcalfe
Journal:  BMJ Open       Date:  2017-07-05       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.